Lysosomal Storage Diseases Therapeutics Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Global Lysosomal Storage Diseases Therapeutics Market estimated at US$7 Billion in the year 2020, is projected to reach a revised size of US$10.3 Billion by 2028, growing at a CAGR of 5% during the forecast period 2022-2028.

Lysosomal storage disorders (LSDs) are a group of rare genetic metabolic disorders caused by defects in lysosomal function. The absence of lysosomal enzymes, such as hydrolases, which are responsible for the breakdown of specific substrates, activators, or transporters lead to the accumulation of substrates, leading to LSD. Examples of LSD include mucopolysaccharides, mucoliposaccharides, oligosaccharides, Pompe disease, Gaucher disease, Fabry disease, Niemann-Pick disorder, and neuronal celloid lipofuscinose.

Market Segments

By Treatment

• Enzyme Replacement Therapy
• Stem Cell Therapy
• Substrate Reduction Therapy
• Others

By Indication

• Gaucher’s Disease
• Fabry Disease
• Pompe’s Syndrome
• Mucopolysaccharidosis

Key Players

• Shire PLC
• Pfizer, Inc.
• Sanofi
• BioMarin Pharmaceutical Inc.
• Actelion Ltd.
• Raptor Pharmaceutical Corp.
• Protalix Biotherapeutics Inc.
• Amicus Therapeutics, Inc.

Scope of the Report

The research study analyzes the global Lysosomal Storage Diseases Therapeutics industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Lysosomal Storage Diseases Therapeutics Market Report

1. What was the Lysosomal Storage Diseases Therapeutics Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Lysosomal Storage Diseases Therapeutics Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Lysosomal Storage Diseases Therapeutics Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.